- Trials with a EudraCT protocol (165)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
165 result(s) found for: Membrane Potential.
Displaying page 1 of 9.
EudraCT Number: 2017-002927-68 | Sponsor Protocol Number: 2002C015G | Start Date*: 2017-11-08 | |||||||||||
Sponsor Name:Prometic Biotherapeutics Ltd | |||||||||||||
Full Title: A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Pe... | |||||||||||||
Medical condition: Tympanic Membrane Perforation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005429-21 | Sponsor Protocol Number: OPTIMIST-Aprotocol | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Menzies Research Institute Tasmania | |||||||||||||
Full Title: Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP) | |||||||||||||
Medical condition: Infant respiratory distress syndrome, also known as hyaline membrane disease. | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA SI (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004419-11 | Sponsor Protocol Number: SC35 | Start Date*: 2017-04-20 | ||||||||||||||||
Sponsor Name:Radboud university medical center | ||||||||||||||||||
Full Title: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem c... | ||||||||||||||||||
Medical condition: Mucositis and febrile neutropenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004082-39 | Sponsor Protocol Number: GOOD-IDES-01 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Linköping University | |||||||||||||
Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | |||||||||||||
Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004853-26 | Sponsor Protocol Number: T315/2018 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:Turku University Hospital | ||||||||||||||||||
Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer | ||||||||||||||||||
Medical condition: Metastatic prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: FI (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001747-21 | Sponsor Protocol Number: ISPUP2020CT1 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Instituto de Saúde Pública Universidade Porto | |||||||||||||
Full Title: Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial | |||||||||||||
Medical condition: Novel coronavirus pneumonia (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001193-15 | Sponsor Protocol Number: FASTERCC-001 | Start Date*: 2016-07-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Department of Oncology, Aarhus University Hospital | |||||||||||||||||||||||||||||||||
Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ... | |||||||||||||||||||||||||||||||||
Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003226-71 | Sponsor Protocol Number: MR42410 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ... | |||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004741-37 | Sponsor Protocol Number: 212458 | Start Date*: 2021-06-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt... | ||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Ongoing) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019991-55 | Sponsor Protocol Number: CC-10004-PSOR-008 | Start Date*: 2011-01-25 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018386-32 | Sponsor Protocol Number: CC-10004-PSA-003 | Start Date*: 2010-12-27 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | |||||||||||||
Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001555-37 | Sponsor Protocol Number: CC-10004-AS-001 | Start Date*: 2012-09-04 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyl... | |||||||||||||
Medical condition: Ankylosing spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) CZ (Completed) AT (Completed) BG (Completed) FR (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000489-37 | Sponsor Protocol Number: SURF-04-01 | Start Date*: 2005-08-26 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery... | ||
Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011819-20 | Sponsor Protocol Number: V00067 CA 201 1A | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study. | |||||||||||||
Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003788-13 | Sponsor Protocol Number: 1013 | Start Date*: 2023-09-21 |
Sponsor Name:Heikki Minn | ||
Full Title: Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both? | ||
Medical condition: Metastatic prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002130-30 | Sponsor Protocol Number: NSCLC-TKD/IL-2 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Technische Universität München Fakultät für Medizin | |||||||||||||
Full Title: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) | |||||||||||||
Medical condition: Interventional phase II clinical trial incorporating a parallel control group of patients receiving no adjuvant immunotherapy. Patients with non small lung cell carcinoma (NSCLC) in stage III A and... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019992-30 | Sponsor Protocol Number: CC-10004-PSOR-009 | Start Date*: 2010-12-16 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019926-15 | Sponsor Protocol Number: CC-10004-RA-002 | Start Date*: 2011-01-27 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATO... | |||||||||||||
Medical condition: Rheumatoid arthritis, a chronic systemic autoimmune inflammatory disease characterized by persisten synovial inflammations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022046-25 | Sponsor Protocol Number: Zellweger | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Department of Pediatric Gastroenterology, Academic Medical Centre | ||||||||||||||||||
Full Title: Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. | ||||||||||||||||||
Medical condition: Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorder This syndrome encompasses a spectrum of severity in symptoms Previously the disorder was subdivided into three disorders based... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002972-95 | Sponsor Protocol Number: V72_74 | Start Date*: 2014-12-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Y... | |||||||||||||
Medical condition: Meningococcal Group B disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.